<DOC>
	<DOCNO>NCT01814553</DOCNO>
	<brief_summary>This non-randomized , open label , two-cohort , multi-institutional study evaluate use diarrheal management tool intend facilitate timely intervention treatment modification due afatinib treatment-related diarrhea patient EGFR mutations-positive adenocarcinoma lung . Patients Cohort 1 follow diarrhea management . Patients Cohort 2 receive prophylactic loperamide start fist day afatinib treatment .</brief_summary>
	<brief_title>ADAM-Afatinib Diarrhea Assessment Management</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Loperamide</mesh_term>
	<mesh_term>Antidiarrheals</mesh_term>
	<criteria>Inclusion criterion : 1 . Pathologically confirm diagnosis Stage IIIB Stage IV adenocarcinoma lung , EGFR mutationspositive status , eligible receive surgery chemoradiotherapy . Patients mixed histology eligible adenocarcinoma predominant histology , suitable candidate EGFRTKI monotherapy , opinion investigator . 2 . Patients must Epidermal Growth Factor Receptor ( EGFR ) mutationpositive status accord institutional standard care . 3 . Patient receive one ( 1 ) prior chemotherapy locally advance metastatic adenocarcinoma lung . 4 . Male female patient Age 18 year old . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 6 . Adequate organ function , define follow : Left Ventricular Ejection Fraction ( LVEF ) 50 % within institution normal value Absolute neutrophil count ( ANC ) 1500 / mm3 . Platelet count 75,000 / mm3 . Estimated creatinine clearance 45ml / min . Total Bilirubin le 1.5 time upper limit ( institutional/central ) normal Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) less three time upper limit ( institutional/central ) normal ( ULN ) ( relate liver metastases less five time ULN ) . 7 . Recovered previous therapy relate toxicity Grade 0 1 study entry 8 . Able willing follow diarrhea management guideline provide study complete Diarrhea Management Worksheet instruct . Exclusion criterion : 1 . Chemotherapy , biological therapy investigational agent within four week prior start study treatment . 2 . Prior treatment EGFR direct small molecule antibody . 3 . Hormonal treatment within 2 week prior start study treatment ( continue use antiandrogens and/or gonadorelin analogue treatment prostate cancer permit ) . 4 . Major surgery within 4 week start study treatment schedule surgery project course study . 5 . Known hypersensitivity afatinib excipients trial drug . 6 . History presence clinically relevant cardiovascular abnormality . 7 . Any history concomitant condition , opinion Investigator , would compromise patientÂ¿s ability comply study interfere evaluation efficacy safety test drug . 8 . Previous concomitant invasive malignancy sit . 9 . Known preexist interstitial lung disease ( ILD ) . 10 . Any history presence poorly control gastrointestinal disorder could affect absorption study drug . 14 . Active hepatitis B infection , active hepatitis C infection and/or know HIV carrier , determine investigator suitable candidate receive EGFRTKI treatment . 15 . Patients meningeal carcinomatosis . 16 . Patients brain subdural metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>